Microsoft Excel LibreOffice Calc

Eli Lilly & Co. (LLY)

Analysis of Profitability Ratios
Quarterly Data

Beginner level

Profitability ratios measure the company’s ability to generate profitable sales from its resources (assets).

Profitability Ratios (Summary)

Eli Lilly & Co., profitability ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Return on Sales
Gross profit margin 77.78% 76.67% 74.96% 73.81% 73.39% 72.92% 72.95% 73.46% 73.69% 73.89% 73.78% 73.35% 73.23% 73.72% 74.39% 74.76% 75.13% 74.87% 74.96% 74.85% — — —
Operating profit margin 20.00% 19.48% 12.50% 15.15% 12.34% 9.11% 14.88% 9.38% 12.43% 14.23% 12.92% 16.30% 14.31% 14.56% 14.27% 13.47% 13.53% 11.55% 12.00% 13.56% — — —
Net profit margin 35.10% 33.76% 26.12% 13.16% 1.85% -0.60% 4.82% -0.89% 9.90% 11.12% 10.13% 12.90% 11.73% 11.97% 11.49% 12.07% 11.97% 10.50% 11.20% 12.19% — — —
Return on Investment
Return on equity (ROE) 234.97% 282.08% 252.24% 32.88% 3.44% -1.24% 7.74% -1.76% 14.94% 17.35% 15.58% 19.54% 15.68% 16.85% 15.45% 16.53% 15.49% 14.04% 14.69% 15.55% — — —
Return on assets (ROA) 20.97% 20.28% 16.46% 7.36% 1.01% -0.34% 2.53% -0.45% 5.17% 5.98% 5.81% 7.05% 6.50% 6.76% 6.68% 6.77% 6.50% 5.71% 6.15% 6.43% — — —

Based on: 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-05-01), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-30), 10-Q (filing date: 2015-04-30), 10-K (filing date: 2015-02-19), 10-Q (filing date: 2014-10-29), 10-Q (filing date: 2014-07-28), 10-Q (filing date: 2014-04-28).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Eli Lilly & Co.’s gross profit margin ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Eli Lilly & Co.’s operating profit margin ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Eli Lilly & Co.’s net profit margin ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Eli Lilly & Co.’s ROE improved from Q1 2019 to Q2 2019 but then deteriorated significantly from Q2 2019 to Q3 2019.
ROA A profitability ratio calculated as net income divided by total assets. Eli Lilly & Co.’s ROA improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Gross Profit Margin

Eli Lilly & Co., gross profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in thousands)
Gross margin 4,301,600  4,511,800  3,953,500  4,844,900  4,499,600  4,652,500  4,128,700  4,535,900  4,091,900  4,272,700  3,900,600  4,294,500  3,790,800  3,939,800  3,542,100  3,986,400  3,722,800  3,760,300  3,452,000  3,868,200  3,608,600  3,745,900  3,460,400 
Revenue 5,476,600  5,636,700  5,092,200  6,438,600  6,061,900  6,355,200  5,700,000  6,160,700  5,658,000  5,824,300  5,228,300  5,760,500  5,191,700  5,404,800  4,865,100  5,375,600  4,959,700  4,978,700  4,644,700  5,121,300  4,875,600  4,935,600  4,683,100 
Profitability Ratio
Gross profit margin1 77.78% 76.67% 74.96% 73.81% 73.39% 72.92% 72.95% 73.46% 73.69% 73.89% 73.78% 73.35% 73.23% 73.72% 74.39% 74.76% 75.13% 74.87% 74.96% 74.85% — — —
Benchmarks
Gross Profit Margin, Competitors2
Abbott Laboratories 52.39% 52.17% 51.57% 51.32% 50.57% 50.38% 49.39% 47.75% 48.59% 49.21% 51.32% 54.09% 54.17% 53.99% 53.93% 54.19% 53.83% 53.39% 52.87% 51.73% — — —
AbbVie Inc. 77.32% 77.41% 77.07% 76.44% 75.22% 74.93% 75.18% 75.05% 76.85% 76.78% 76.81% 77.25% 77.21% 78.12% 79.28% 80.31% 81.09% 80.60% 79.12% 77.83% — — —
Allergan PLC 84.96% 85.09% 86.21% 86.12% 86.39% 86.56% 86.03% 86.40% 86.65% 87.11% 87.56% 87.23% 86.55% 81.36% 73.17% 68.08% 62.19% 57.25% 53.50% 51.74% — — —
Amgen Inc. 81.19% 81.23% 81.26% 81.80% 81.61% 81.78% 81.69% 81.33% 81.37% 81.26% 81.05% 80.99% 80.68% 80.64% 80.23% 79.82% 79.13% 78.27% 78.00% 77.12% — — —
Biogen Inc. 85.97% 85.59% 85.72% 86.50% 86.12% 86.43% 86.57% 86.72% 87.34% 86.80% 86.56% 87.08% 87.46% 88.21% 88.65% 88.48% 88.59% 88.36% 88.11% 87.93% — — —
Bristol-Myers Squibb Co. 69.65% 69.93% 70.77% 70.98% 70.37% 70.12% 69.62% 70.80% 71.92% 72.78% 74.19% 74.54% 75.56% 75.55% 75.67% 76.39% 76.27% 76.60% 76.34% 75.24% — — —
Gilead Sciences Inc. 79.27% 78.98% 78.02% 77.61% 79.21% 80.31% 81.82% 82.97% 84.51% 84.71% 85.95% 85.77% 86.36% 86.91% 86.69% 87.54% 87.06% 86.32% 85.72% 84.52% — — —
Johnson & Johnson 66.49% 66.67% 66.80% 66.79% 66.36% 65.69% 66.22% 66.84% 68.20% 69.35% 69.88% 69.84% 69.52% 69.58% 69.25% 69.27% 69.20% 69.55% 69.33% 69.40% — — —
Merck & Co. Inc. 70.13% 69.89% 68.94% 68.06% 67.35% 67.81% 68.22% 68.16% 68.09% 67.92% 66.61% 65.10% 63.89% 62.58% 62.07% 62.19% 62.70% 62.00% 60.30% 60.30% — — —
Pfizer Inc. 79.85% 79.91% 79.36% 79.03% 78.58% 78.24% 78.48% 78.61% 78.66% 78.15% 77.28% 76.66% 76.48% 77.71% 79.09% 80.25% 81.35% 81.14% 80.92% 80.69% — — —
Regeneron Pharmaceuticals Inc. 91.14% 92.27% 92.79% 93.53% 93.36% 93.28% 92.95% 93.24% 93.37% 94.16% 94.53% 93.83% 92.90% 91.38% 90.52% 90.43% 91.04% 91.52% 91.99% 92.73% — — —
Vertex Pharmaceuticals Inc. 86.60% 86.56% 86.74% 86.56% 86.88% 87.31% 87.59% 88.95% 89.04% 89.08% 89.76% 87.64% 87.16% 87.72% 87.39% 87.94% 90.10% 90.87% 90.37% 89.49% — — —
Zoetis Inc. 67.38% 66.92% 66.49% 67.19% 68.12% 68.04% 67.31% 66.55% 65.14% 64.91% 65.30% 65.92% 65.32% 64.90% 64.08% 63.53% 63.98% 63.68% 63.84% 64.12% — — —

Based on: 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-05-01), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-30), 10-Q (filing date: 2015-04-30), 10-K (filing date: 2015-02-19), 10-Q (filing date: 2014-10-29), 10-Q (filing date: 2014-07-28), 10-Q (filing date: 2014-04-28).

1 Q3 2019 Calculation
Gross profit margin = 100 × (Gross marginQ3 2019 + Gross marginQ2 2019 + Gross marginQ1 2019 + Gross marginQ4 2018) ÷ (RevenueQ3 2019 + RevenueQ2 2019 + RevenueQ1 2019 + RevenueQ4 2018)
= 100 × (4,301,600 + 4,511,800 + 3,953,500 + 4,844,900) ÷ (5,476,600 + 5,636,700 + 5,092,200 + 6,438,600) = 77.78%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Eli Lilly & Co.’s gross profit margin ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Operating Profit Margin

Eli Lilly & Co., operating profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in thousands)
Operating income (loss) 1,430,700  1,498,300  645,100  954,200  1,426,400  (33,200) 1,373,500  229,000  605,500  1,264,400  46,100  876,200  943,500  923,300  715,800  399,900  961,300  803,000  525,200  376,400  562,000  886,600  834,800 
Revenue 5,476,600  5,636,700  5,092,200  6,438,600  6,061,900  6,355,200  5,700,000  6,160,700  5,658,000  5,824,300  5,228,300  5,760,500  5,191,700  5,404,800  4,865,100  5,375,600  4,959,700  4,978,700  4,644,700  5,121,300  4,875,600  4,935,600  4,683,100 
Profitability Ratio
Operating profit margin1 20.00% 19.48% 12.50% 15.15% 12.34% 9.11% 14.88% 9.38% 12.43% 14.23% 12.92% 16.30% 14.31% 14.56% 14.27% 13.47% 13.53% 11.55% 12.00% 13.56% — — —
Benchmarks
Operating Profit Margin, Competitors2
Abbott Laboratories 13.74% 13.27% 12.31% 11.94% 10.45% 10.11% 8.92% 6.30% 7.89% 8.77% 11.03% 15.27% 14.74% 13.95% 13.64% 14.05% 14.00% 14.13% 13.95% 12.84% — — —
AbbVie Inc. 20.04% 21.85% 19.88% 19.49% 32.99% 32.84% 34.03% 33.99% 37.24% 36.74% 36.33% 36.60% 36.21% 35.00% 34.18% 32.97% 22.86% 19.46% 18.33% 17.09% — — —
Allergan PLC -60.39% -55.48% -50.30% -39.57% -5.95% -32.39% -35.34% -37.15% -43.48% -19.74% -17.36% -12.53% -13.13% -20.47% -15.77% -20.00% -17.09% -15.71% -16.60% -9.71% — — —
Amgen Inc. 44.83% 44.05% 44.53% 45.55% 45.82% 46.46% 46.07% 45.76% 46.66% 46.93% 45.68% 44.74% 43.33% 42.46% 41.53% 40.44% 37.98% 34.90% 34.51% 32.03% — — —
Biogen Inc. 47.13% 46.90% 42.40% 43.77% 44.67% 45.58% 46.49% 43.54% 40.25% 38.72% 41.59% 44.99% 47.59% 47.86% 47.11% 45.44% 46.21% 45.28% 43.63% 40.94% — — —
Bristol-Myers Squibb Co. 28.64% 28.60% 23.44% 22.69% 18.64% 15.93% 17.50% 17.39% 19.71% 21.73% 24.06% 23.83% 19.21% 16.34% 11.09% 11.41% 16.40% 16.96% 18.39% 16.32% — — —
Gilead Sciences Inc. 19.71% 38.44% 37.87% 37.83% 42.81% 46.25% 51.51% 55.04% 58.72% 58.71% 58.46% 58.87% 61.67% 63.83% 66.22% 69.03% 67.51% 65.45% 65.14% 62.37% — — —
Johnson & Johnson 24.15% 22.63% 22.69% 24.27% 22.59% 23.05% 23.63% 24.07% 27.02% 28.55% 28.83% 28.72% 26.37% 25.66% 25.00% 25.05% 26.50% 27.31% 28.10% 28.20% — — —
Merck & Co. Inc. 25.56% 26.73% 24.38% 19.62% 17.84% 12.28% 13.57% 16.28% 9.92% 16.85% 14.45% 13.51% 19.60% 18.10% 18.19% 17.54% 16.06% 13.62% 12.51% 13.42% — — —
Pfizer Inc. 26.30% 27.50% 26.86% 26.10% 26.18% 26.00% 25.86% 25.92% 24.69% 23.57% 22.94% 22.73% 22.96% 24.02% 24.86% 24.20% 25.33% 25.85% 26.09% 26.71% — — —
Regeneron Pharmaceuticals Inc. 29.55% 29.58% 35.41% 37.77% 37.00% 36.89% 36.54% 35.41% 34.22% 32.29% 28.76% 27.38% 25.67% 26.77% 29.26% 30.51% 33.30% 31.17% 30.56% 29.74% — — —
Vertex Pharmaceuticals Inc. 21.38% 25.48% 23.98% 20.84% 22.38% 3.87% -0.77% 4.95% 1.62% 16.16% 14.62% 0.58% -5.02% -8.65% -23.94% -45.23% -74.68% -101.73% -107.97% -119.30% — — —
Zoetis Inc. 31.01% 29.80% 30.05% 31.12% 33.00% 33.86% 33.02% 32.15% 29.43% 28.34% 28.55% 28.48% 26.22% 24.91% 17.35% 15.74% 15.40% 14.81% 19.73% 19.73% — — —

Based on: 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-05-01), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-30), 10-Q (filing date: 2015-04-30), 10-K (filing date: 2015-02-19), 10-Q (filing date: 2014-10-29), 10-Q (filing date: 2014-07-28), 10-Q (filing date: 2014-04-28).

1 Q3 2019 Calculation
Operating profit margin = 100 × (Operating income (loss)Q3 2019 + Operating income (loss)Q2 2019 + Operating income (loss)Q1 2019 + Operating income (loss)Q4 2018) ÷ (RevenueQ3 2019 + RevenueQ2 2019 + RevenueQ1 2019 + RevenueQ4 2018)
= 100 × (1,430,700 + 1,498,300 + 645,100 + 954,200) ÷ (5,476,600 + 5,636,700 + 5,092,200 + 6,438,600) = 20.00%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Eli Lilly & Co.’s operating profit margin ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Net Profit Margin

Eli Lilly & Co., net profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in thousands)
Net income (loss) 1,253,900  1,327,200  4,241,600  1,125,000  1,149,500  (259,900) 1,217,400  (1,656,900) 555,600  1,008,000  (110,800) 771,800  778,000  747,700  440,100  478,400  799,700  600,800  529,500  428,500  500,600  733,500  727,900 
Revenue 5,476,600  5,636,700  5,092,200  6,438,600  6,061,900  6,355,200  5,700,000  6,160,700  5,658,000  5,824,300  5,228,300  5,760,500  5,191,700  5,404,800  4,865,100  5,375,600  4,959,700  4,978,700  4,644,700  5,121,300  4,875,600  4,935,600  4,683,100 
Profitability Ratio
Net profit margin1 35.10% 33.76% 26.12% 13.16% 1.85% -0.60% 4.82% -0.89% 9.90% 11.12% 10.13% 12.90% 11.73% 11.97% 11.49% 12.07% 11.97% 10.50% 11.20% 12.19% — — —
Benchmarks
Net Profit Margin, Competitors2
Abbott Laboratories 10.50% 9.36% 8.53% 7.74% 2.91% 3.13% 1.67% 1.74% 8.37% 4.96% 6.74% 6.71% 6.61% 11.08% 12.00% 21.68% 22.17% 22.04% 20.60% 11.28% — — —
AbbVie Inc. 9.90% 12.62% 16.42% 17.36% 23.50% 20.84% 21.55% 18.82% 24.38% 24.77% 24.07% 23.22% 24.08% 23.11% 23.03% 22.50% 12.86% 9.93% 8.89% 8.89% — — —
Allergan PLC -58.50% -54.25% -45.94% -32.28% 14.50% -9.86% -11.51% -25.88% -46.82% 79.17% 82.42% 102.76% 107.27% 31.97% 29.44% 25.98% 23.16% -15.76% -17.26% -12.48% — — —
Amgen Inc. 36.14% 35.57% 35.93% 37.25% 9.96% 10.72% 10.11% 9.08% 37.36% 37.24% 36.12% 35.27% 35.19% 34.48% 33.86% 33.13% 30.94% 28.90% 28.76% 26.69% — — —
Biogen Inc. 37.91% 37.62% 33.79% 32.93% 24.08% 23.06% 23.54% 20.69% 29.44% 28.10% 30.17% 32.34% 34.03% 33.97% 33.79% 32.95% 34.06% 33.89% 32.36% 30.25% — — —
Bristol-Myers Squibb Co. 23.39% 26.00% 22.09% 21.81% 6.50% 1.74% 4.37% 4.85% 20.56% 22.66% 24.22% 22.94% 18.22% 16.29% 9.31% 9.45% 10.74% 10.93% 13.99% 12.62% — — —
Gilead Sciences Inc. 12.24% 27.14% 26.93% 25.16% 7.27% 9.69% 14.26% 18.03% 42.90% 43.55% 44.11% 45.07% 48.40% 51.16% 53.48% 56.32% 54.62% 52.38% 52.60% 49.44% — — —
Johnson & Johnson 17.32% 20.08% 17.99% 18.75% 1.89% 1.70% 1.58% 1.70% 21.28% 22.52% 22.87% 23.01% 22.27% 21.20% 22.15% 21.99% 20.87% 22.41% 21.63% 21.96% — — —
Merck & Co. Inc. 20.26% 21.10% 19.50% 14.71% 8.02% 3.25% 3.88% 5.97% 7.15% 12.71% 10.88% 9.85% 13.76% 13.01% 11.72% 11.25% 27.11% 24.48% 26.98% 28.22% — — —
Pfizer Inc. 30.57% 23.58% 21.31% 20.79% 44.63% 42.35% 41.29% 40.55% 18.69% 15.90% 13.88% 13.66% 11.77% 13.47% 14.95% 14.25% 17.45% 18.46% 18.69% 18.42% — — —
Regeneron Pharmaceuticals Inc. 28.13% 28.59% 35.12% 36.42% 28.24% 25.65% 23.54% 20.41% 23.17% 22.05% 19.34% 18.42% 16.85% 15.98% 16.72% 15.50% 15.53% 13.56% 11.71% 12.34% — — —
Vertex Pharmaceuticals Inc. 59.23% 64.13% 66.01% 68.80% 22.87% 15.84% 9.36% 10.59% 8.53% 12.19% 8.78% -6.58% -13.17% -17.66% -30.91% -53.89% -86.86% -116.88% -117.36% -127.25% — — —
Zoetis Inc. 23.76% 22.74% 23.47% 24.52% 20.35% 19.95% 17.97% 16.28% 18.29% 17.50% 17.25% 16.80% 14.10% 13.15% 7.83% 7.11% 9.21% 8.74% 12.38% 12.18% — — —

Based on: 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-05-01), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-30), 10-Q (filing date: 2015-04-30), 10-K (filing date: 2015-02-19), 10-Q (filing date: 2014-10-29), 10-Q (filing date: 2014-07-28), 10-Q (filing date: 2014-04-28).

1 Q3 2019 Calculation
Net profit margin = 100 × (Net income (loss)Q3 2019 + Net income (loss)Q2 2019 + Net income (loss)Q1 2019 + Net income (loss)Q4 2018) ÷ (RevenueQ3 2019 + RevenueQ2 2019 + RevenueQ1 2019 + RevenueQ4 2018)
= 100 × (1,253,900 + 1,327,200 + 4,241,600 + 1,125,000) ÷ (5,476,600 + 5,636,700 + 5,092,200 + 6,438,600) = 35.10%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Eli Lilly & Co.’s net profit margin ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Return on Equity (ROE)

Eli Lilly & Co., ROE calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in thousands)
Net income (loss) 1,253,900  1,327,200  4,241,600  1,125,000  1,149,500  (259,900) 1,217,400  (1,656,900) 555,600  1,008,000  (110,800) 771,800  778,000  747,700  440,100  478,400  799,700  600,800  529,500  428,500  500,600  733,500  727,900 
Total Eli Lilly and Company shareholders’ equity 3,382,500  2,780,500  2,480,300  9,828,700  13,076,600  11,555,200  14,527,000  11,592,200  14,890,300  14,100,800  14,031,000  14,007,700  15,589,200  14,637,300  15,009,900  14,571,300  15,221,400  14,670,300  14,919,800  15,373,200  17,669,300  17,983,700  18,338,100 
Profitability Ratio
ROE1 234.97% 282.08% 252.24% 32.88% 3.44% -1.24% 7.74% -1.76% 14.94% 17.35% 15.58% 19.54% 15.68% 16.85% 15.45% 16.53% 15.49% 14.04% 14.69% 15.55% — — —
Benchmarks
ROE, Competitors2
Abbott Laboratories 10.35% 9.14% 8.48% 7.76% 2.89% 3.03% 1.52% 1.54% 6.57% 3.71% 4.79% 6.82% 6.59% 11.02% 11.81% 20.85% 21.60% 19.64% 19.21% 10.61% — — —
AbbVie Inc. — — — — — — 179.59% 104.16% 99.42% 110.08% 126.25% 128.41% 93.97% 101.42% 117.94% 130.39% 57.93% 37.86% 131.88% 101.84% — — —
Allergan PLC -15.82% -14.25% -11.73% -7.83% 3.30% -2.24% -2.55% -5.59% -10.18% 15.86% 16.16% 19.65% 15.99% 5.77% 6.05% 5.11% 4.92% -3.51% -3.14% -5.76% — — —
Amgen Inc. 73.83% 73.73% 74.55% 67.15% 15.35% 15.86% 14.21% 7.84% 25.37% 25.77% 25.76% 25.85% 24.65% 24.67% 25.16% 24.71% 23.00% 21.15% 21.53% 20.01% — — —
Biogen Inc. 38.55% 40.87% 33.74% 33.98% 23.15% 24.21% 21.09% 20.13% 27.10% 28.42% 30.31% 30.50% 32.06% 33.48% 35.78% 37.84% 34.04% 27.76% 28.09% 27.15% — — —
Bristol-Myers Squibb Co. 32.04% 38.65% 33.80% 35.07% 10.50% 3.05% 7.18% 8.58% 28.61% 31.20% 33.55% 27.55% 21.56% 19.24% 10.94% 10.97% 11.77% 11.84% 14.49% 13.49% — — —
Gilead Sciences Inc. 13.07% 26.33% 26.84% 25.51% 6.94% 10.19% 16.82% 22.64% 46.69% 53.86% 61.82% 71.48% 89.38% 105.21% 129.43% 97.70% 97.12% 92.36% 82.69% 78.45% — — —
Johnson & Johnson 24.31% 26.87% 24.90% 25.60% 2.39% 2.18% 1.97% 2.16% 21.39% 22.71% 23.46% 23.49% 21.91% 20.73% 21.40% 21.66% 20.56% 22.64% 23.45% 23.40% — — —
Merck & Co. Inc. 34.70% 33.88% 30.50% 23.30% 10.32% 4.12% 4.69% 6.97% 7.44% 12.89% 10.91% 9.78% 12.55% 11.84% 10.53% 9.94% 23.65% 21.21% 23.38% 24.50% — — —
Pfizer Inc. 24.91% 21.24% 19.52% 17.59% 33.40% 32.31% 29.72% 29.88% 16.14% 14.26% 12.49% 12.12% 9.90% 11.22% 12.09% 10.75% 12.51% 13.30% 13.64% 12.81% — — —
Regeneron Pharmaceuticals Inc. 20.41% 21.21% 25.70% 27.91% 22.85% 22.14% 21.74% 19.51% 21.12% 20.91% 19.79% 20.13% 17.75% 18.23% 19.69% 17.40% 17.93% 13.80% 12.07% 13.69% — — —
Vertex Pharmaceuticals Inc. 40.81% 43.70% 45.63% 47.28% 22.27% 15.46% 9.41% 12.99% 10.93% 15.55% 11.82% -9.69% -21.41% -28.03% -41.73% -59.19% -71.49% -82.03% -72.17% -68.70% — — —
Zoetis Inc. 54.56% 57.03% 59.91% 65.35% 54.96% 56.60% 49.90% 48.81% 47.11% 51.20% 53.14% 55.21% 43.47% 47.09% 32.45% 31.74% 36.05% 35.71% 46.40% 44.47% — — —

Based on: 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-05-01), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-30), 10-Q (filing date: 2015-04-30), 10-K (filing date: 2015-02-19), 10-Q (filing date: 2014-10-29), 10-Q (filing date: 2014-07-28), 10-Q (filing date: 2014-04-28).

1 Q3 2019 Calculation
ROE = 100 × (Net income (loss)Q3 2019 + Net income (loss)Q2 2019 + Net income (loss)Q1 2019 + Net income (loss)Q4 2018) ÷ Total Eli Lilly and Company shareholders’ equity
= 100 × (1,253,900 + 1,327,200 + 4,241,600 + 1,125,000) ÷ 3,382,500 = 234.97%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Eli Lilly & Co.’s ROE improved from Q1 2019 to Q2 2019 but then deteriorated significantly from Q2 2019 to Q3 2019.

Return on Assets (ROA)

Eli Lilly & Co., ROA calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in thousands)
Net income (loss) 1,253,900  1,327,200  4,241,600  1,125,000  1,149,500  (259,900) 1,217,400  (1,656,900) 555,600  1,008,000  (110,800) 771,800  778,000  747,700  440,100  478,400  799,700  600,800  529,500  428,500  500,600  733,500  727,900 
Total assets 37,893,100  38,666,400  38,006,800  43,908,400  44,625,100  42,359,200  44,355,600  44,981,000  43,010,400  40,946,500  37,624,300  38,805,900  37,590,300  36,475,300  34,691,800  35,568,900  36,304,700  36,036,600  35,653,900  37,178,200  34,648,800  35,018,400  34,756,900 
Profitability Ratio
ROA1 20.97% 20.28% 16.46% 7.36% 1.01% -0.34% 2.53% -0.45% 5.17% 5.98% 5.81% 7.05% 6.50% 6.76% 6.68% 6.77% 6.50% 5.71% 6.15% 6.43% — — —
Benchmarks
ROA, Competitors2
Abbott Laboratories 4.80% 4.23% 3.88% 3.53% 1.24% 1.35% 0.67% 0.63% 2.91% 1.65% 2.12% 2.66% 3.47% 5.72% 6.17% 10.72% 10.93% 10.24% 9.75% 5.53% — — —
AbbVie Inc. 5.48% 7.21% 9.44% 9.58% 11.43% 10.46% 9.20% 7.50% 9.66% 9.87% 9.61% 9.01% 9.12% 8.51% 10.19% 9.70% 5.14% 3.87% 6.80% 6.44% — — —
Allergan PLC -9.80% -8.91% -7.36% -5.01% 2.18% -1.46% -1.65% -3.49% -6.09% 9.56% 9.58% 11.61% 9.99% 3.34% 3.44% 2.88% 2.67% -1.83% -1.61% -3.10% — — —
Amgen Inc. 13.55% 13.40% 12.62% 12.64% 3.27% 3.49% 3.12% 2.48% 10.18% 10.27% 10.14% 9.95% 9.71% 9.85% 9.61% 9.69% 8.95% 8.16% 8.28% 7.47% — — —
Biogen Inc. 19.63% 20.14% 17.65% 17.52% 12.50% 12.39% 11.36% 10.73% 15.11% 15.13% 16.42% 16.19% 17.58% 17.75% 17.87% 18.19% 17.36% 20.83% 21.53% 20.50% — — —
Bristol-Myers Squibb Co. 9.85% 11.24% 14.77% 14.06% 4.24% 1.15% 2.78% 3.00% 12.45% 13.73% 14.68% 13.22% 9.98% 8.74% 4.94% 4.93% 5.59% 5.60% 6.71% 5.94% — — —
Gilead Sciences Inc. 4.55% 9.42% 9.38% 8.57% 2.47% 3.38% 5.30% 6.58% 17.94% 20.27% 21.90% 23.70% 26.63% 32.71% 36.30% 34.93% 33.40% 38.41% 37.07% 34.91% — — —
Johnson & Johnson 9.10% 10.53% 9.78% 10.00% 0.99% 0.88% 0.79% 0.83% 10.17% 10.69% 11.39% 11.71% 11.36% 10.75% 11.41% 11.55% 11.04% 12.20% 12.38% 12.45% — — —
Merck & Co. Inc. 11.18% 11.15% 10.20% 7.53% 3.93% 1.58% 1.84% 2.72% 3.11% 5.48% 4.50% 4.11% 5.58% 5.32% 4.67% 4.36% 10.65% 9.60% 10.31% 12.12% — — —
Pfizer Inc. 9.51% 8.10% 7.38% 7.00% 14.19% 13.67% 13.21% 12.40% 5.70% 4.94% 4.32% 4.20% 3.51% 4.13% 4.68% 4.16% 4.89% 5.53% 5.72% 5.40% — — —
Regeneron Pharmaceuticals Inc. 15.38% 15.71% 18.88% 20.83% 16.64% 15.99% 15.23% 13.67% 14.69% 14.24% 12.32% 12.84% 11.68% 11.97% 12.56% 11.34% 11.41% 10.17% 8.54% 8.99% — — —
Vertex Pharmaceuticals Inc. 28.53% 31.50% 32.94% 33.57% 14.00% 9.58% 5.72% 7.43% 6.12% 7.91% 6.02% -3.87% -8.38% -10.79% -16.05% -22.26% -27.09% -30.92% -32.54% -31.63% — — —
Zoetis Inc. 12.96% 12.52% 12.75% 13.25% 11.13% 12.96% 11.25% 10.06% 10.09% 11.25% 11.18% 10.73% 8.93% 8.50% 5.07% 4.28% 6.63% 6.37% 9.22% 8.82% — — —

Based on: 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-05-01), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-30), 10-Q (filing date: 2015-04-30), 10-K (filing date: 2015-02-19), 10-Q (filing date: 2014-10-29), 10-Q (filing date: 2014-07-28), 10-Q (filing date: 2014-04-28).

1 Q3 2019 Calculation
ROA = 100 × (Net income (loss)Q3 2019 + Net income (loss)Q2 2019 + Net income (loss)Q1 2019 + Net income (loss)Q4 2018) ÷ Total assets
= 100 × (1,253,900 + 1,327,200 + 4,241,600 + 1,125,000) ÷ 37,893,100 = 20.97%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Eli Lilly & Co.’s ROA improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.